News

Between 34.5% and 48.1% achieved at least 10% weight loss. In Lilly’s phase 2b trial, up to 90% and 71% of patients, respectively, lost at least 5% and 10% of their body weight.
ACHIEVE-1 is a phase 3 trial, which evaluated the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
CBSE Class 10 Exam New Rule 2026: The second phase scheduled in May will be optional for students who wish to improve their performance, they said.
This paper presents an active topology for power decoupling in single-phase ac-dc converters, featuring the effective suppression of low-frequency power ripple which is an inherent problem in ...
In this article, the detailed steps for the derivation of linearized minimum current stress modulation scheme for single-phase bidirectional and isolated dual active bridge ac–dc converters is ...
Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs ...
We did a single-centre, dose-escalation and dose-expansion, phase 1/2, clinical trial. Patients with treatment-naive higher-risk-myelodysplastic syndromes or chronic myelomonocytic leukaemia (risk ...
A total of 59.1% of the 1.2-mg cohort and 52.1% of the 1.8-mg cohort saw their MASH resolve without a worsening of fibrosis, compared to 19.1% of the placebo cohort, hitting one of the trial’s ...
RICHMOND, Va. (WAVY) — Virginia’s ban on Styrofoam is set to take effect July 1, four years after legislators approved its phase-out, with the reception getting mixed reviews despite what ...
We conducted a phase 1–2 study of zimislecel in persons with type 1 diabetes. In part A, participants received a half dose of zimislecel (0.4×10 9 cells) as a single infusion into the portal ...
Conference Call Sionna will host a conference call today, June 4, 2025, at 8:00 a.m. ET to discuss the positive Phase 1 results for SION-719 and SION-451 and the Company’s development strategy.